Ultra-Committed
- - - To transform the lives of as many people living with rare diseases as possible, we dedicate ourselves every day to the development and delivery of treatments of rare diseases where none currently exist.
  - - Ultra-Committed
      Learn more
  - Ultra-committed
Research
- - - We develop therapies for rare and ultrarare genetic diseases by exploring an array of drug modalities to select the best treatment strategy for each genetic disease we are studying.
  - - Research
      Learn more
Medicines
Partnerships
Join Our Team
- - - We have built a talented team and a vibrant, people-first culture. We share a passion for helping those living with rare diseases.
  - - Join our team
      Learn More
  - Join Our Team
Newsroom
- - - Access news releases, presentations, and blog posts to follow the latest developments at Ultragenyx.
  - - Newsroom
      Learn More
  - Newsroom
Investors
- - Investor Relations

SEC
filing details

Document Details

Form

Filing Date

Apr 26, 2024

Document Date

Jun 18, 2024

Form Description

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Filing Group

Proxy Filings

Company

Ultragenyx Pharmaceutical Inc.

Issuer

Ultragenyx Pharmaceutical Inc.

Filing Formats

iXBRL

View HTML

XBRL

XBRL Viewer

EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

EX-101.DEF - XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE

EX-101.LAB - XBRL TAXONOMY EXTENSION - LABEL LINKBASE

EX-101.PRE - XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE

XML - XBRL INSTANCE DOCUMENT